MedPath

Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University

Phase 2
Conditions
Covid19
Registration Number
NCT04885764
Lead Sponsor
Ain Shams University
Brief Summary

This is a prospective intervention study to assess the effectiveness of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection

Detailed Description

This is a prospective intervention study to assess the short-term effectiveness of the first dose of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection by monitoring the antibodies (IgG, IgM and level of neutralizing antibodies) in sera of post-vaccinated persons.

The study also will monitor the incidence of SARS-CoV-2 infection among vaccinees just before the first dose administration, 3 weeks after immunization, at the administration of the second dose, 14 days following the second dose and after 3 and 6 months.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
4000
Inclusion Criteria
  1. Age > 18 years old
  2. Candidate for receiving vaccination according to health care authorties prioritaizaton
Exclusion Criteria
  1. SARS-CoV-2 recovered cases <3 months
  2. Individuals who are currently infected with Sars-COV-2 and/or with respiratory symptoms with fever.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Short-term effectiveness21 days of the first dose of vaccine

Assess the short-term effectiveness of the first dose of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection by monitoring the antibodies (IgG, IgM and level of neutralizing antibodies) in sera of postvaccinated persons three weeks after first dose

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center

🇪🇬

Cairo, Non-US, Egypt

© Copyright 2025. All Rights Reserved by MedPath